This is a single-dose, double-blind, placebo-controlled, parallel group safety, tolerability and pharmacodynamic study of subcutaneously (SC) administered REGN88 in rheumatoid arthritis patients who are receiving concomitant methotrexate. Four (4) parallel groups of 8 subjects each with active rheumatoid arthritis will be dosed SC.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
32
Institute of Rheumatology under the Russian Academy of Medical Sciences
Moscow, Russia
hs-C reactive protein (hs-CRP)
Time frame: 43 Days
Subject's Assessment of Pain and Subject's Global Assessment of Disease activity
Time frame: 43 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.